share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4:持股变动声明-高管 Gibson Christopher
美股SEC公告 ·  08/26 16:46

Moomoo AI 已提取核心信息

Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
Recursion Pharmaceuticals首席执行官Christopher Gibson于2024年8月26日购买了公司的5,000股A类普通股。本次交易的价格为每股$2.48,总投资金额为$12,400。在此次交易后,Gibson在Recursion Pharmaceuticals的直接持股增至总共742,656股。该交易目前正在进行中,属于行使或转换衍生证券的范畴。
Recursion Pharmaceuticals首席执行官Christopher Gibson于2024年8月26日购买了公司的5,000股A类普通股。本次交易的价格为每股$2.48,总投资金额为$12,400。在此次交易后,Gibson在Recursion Pharmaceuticals的直接持股增至总共742,656股。该交易目前正在进行中,属于行使或转换衍生证券的范畴。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息